The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Funding Opportunities

2025 AACR-Novocure grants for cancer research now accepting applications

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The American Association for Cancer Research-Novocure Career Development Award for Cancer Research represents a joint effort to promote and support early-career investigators who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage early-career investigators to enter the TTFields research field. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

By Otis W. Brawley and Paul Goldberg
Clinical Roundup

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet. 
PodcastThe Directors

The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it”

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 
By Paul Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account